RT Journal Article
SR Electronic
T1 The Impact of the “Muslim Ban” Executive Order on Healthcare Utilization in Minneapolis-St. Paul, Minnesota
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.23.20218628
DO 10.1101/2020.10.23.20218628
A1 Elizabeth A. Samuels
A1 Lilla Orr
A1 Elizabeth B. White
A1 Altaf Saadi
A1 Aasim I. Padela
A1 Michael Westerhaus
A1 Aarti D. Bhatt
A1 Pooja Agrawal
A1 Dennis Wang
A1 Gregg Gonsalves
YR 2020
UL http://medrxiv.org/content/early/2020/10/28/2020.10.23.20218628.abstract
AB Objective Determine whether the 2017 “Muslim Ban” Executive Order impacted healthcare utilization by people born in Order-targeted nations living in the United States.Methods We conducted a retrospective cohort study of people living in Minneapolis-St. Paul, MN in 2016-2017 who were: 1) born in Order-targeted nations, 2) born in Muslim-majority nations not listed in the Order, and 3) born in the United States and non-Latinx. Primary outcomes were: 1) primary care visits, 2) missed primary care appointments, 3) primary care diagnoses for stress-responsive conditions, 4) emergency department visits, and 5) emergency department visits for stress-responsive diagnoses. We evaluated visit trends before and after Order issuance using linear regression and differences between study groups using a difference-in-difference analyses.Results In early 2016, primary care visits and stress-responsive diagnoses increased among individuals from Muslim majority nations. Following the Order, there was an immediate increase in emergency department visits among individuals from Order-targeted nations.Conclusions Increases in healthcare utilization among people born in Muslim majority countries before and after the “Muslim Ban” likely reflect elevated cumulative stress including the impact of the Order.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was not supported by any direct grant funding. Dr. Gonsalves is supported by the National Institutes of Health National Institute on Drug Abuse (1DP2DA049282-01 and 2 R37 DA15612-16) and the National Institute of Allergy and Infectious Diseases (5R01AI042006-23). Dr. Padela receives grant support from the US Department of Health and Human Services Health Resources and Services Administration, the Greenwall Making a Difference Program, and Patient Centered Outcomes Research Institute. Dr. Samuels is supported by an Advance Clinical and Translational Research (Advance-CTR U54GM115677) Mentored Research Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the HealthPartners and Yale Institutional Review Boards.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available for review upon request.